Ribomic Inc
TSE:4591
Intrinsic Value
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. [ Read More ]
The intrinsic value of one Ribomic Inc stock under the Base Case scenario is 49.36 JPY. Compared to the current market price of 81 JPY, Ribomic Inc is Overvalued by 39%.
Valuation Backtest
Ribomic Inc
Run backtest to discover the historical profit from buying and selling Ribomic Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ribomic Inc
Current Assets | 3.7B |
Cash & Short-Term Investments | 3.6B |
Receivables | 48.1m |
Other Current Assets | 119m |
Non-Current Assets | 51.4m |
PP&E | 14.1m |
Other Non-Current Assets | 37.4m |
Current Liabilities | 201.2m |
Accrued Liabilities | 18.8m |
Other Current Liabilities | 182.4m |
Non-Current Liabilities | 1k |
Other Non-Current Liabilities | 1k |
Earnings Waterfall
Ribomic Inc
Revenue
|
62.6m
JPY
|
Operating Expenses
|
-1.2B
JPY
|
Operating Income
|
-1.1B
JPY
|
Other Expenses
|
127.3m
JPY
|
Net Income
|
-979.1m
JPY
|
Free Cash Flow Analysis
Ribomic Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Ribomic Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Ribomic Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Ribomic Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Ribomic Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Ribomic Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 25 full-time employees. The company went IPO on 2014-09-25. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
Contact
IPO
Employees
Officers
The intrinsic value of one Ribomic Inc stock under the Base Case scenario is 49.36 JPY.
Compared to the current market price of 81 JPY, Ribomic Inc is Overvalued by 39%.